Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meldonium and individualized physical activity in chronic heart failure with preserved ejection fraction
2023-509804-14-00Phase 4Authorised
- Sponsor
- Pauls Stradins Clinical University Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of meldonium in heart failure with preserved ejection fraction (HFpEF), sponsored by Pauls Stradins Clinical University Hospital. Primary endpoint: Change in physical activity tolerance (VO2 max). Planned start Mar 2024; status: authorised.
02
Drugs
meldonium
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2023-509804-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509804-14-00.